parallelism and research on functions with continuously independent data and intensive memory access using opencl

连续的数据无关是指计算目标矩阵连续的元素时使用的源矩阵元素之间没有关系且也为连续的,访存密集型是指函数的计算量较小,但是有大量的数据传输操作。在OpenCL框架下,以bitwise函数为例,研究和实现了连续数据无关访存密集型函数在GPU平台上的并行与优化。在考察向量化、线程组织方式和指令选择优化等多个优化角度在不同的GPU硬件平台上对性能的影响之后,实现了这个函数的跨平台性能移植。实验结果表明,在不考虑数据传输的前提下,优化后的函数与这个函数在OpenCV库中的CPU版本相比,在AMD HD 5850GPU达到了平均40倍的性能加速比;在AMD HD 7970GPU达到了平均90倍的性能加速比;在NVIDIA Tesla C2050GPU上达到了平均60倍的性能加速比;同时,与这个函数在OpenCV库中的CUDA实现相比,在NVIDIA Tesla C2050平台上也达到了1.5倍的性能加速。国家自然科学基金资助项目(60303020,60533020),国家自然科学基金资助重点项目(60503020),国家自然科学基金青年基金课题(61100072)|国家“863”计划基金资助项目(2012AA010902)|ISCAS-AMD联合fusion软件中心资助Continuously independent data type means when calculating the continuous elements of destination matrix, the used elements of source matrices are also continuous and there are no relationship among them. Intensive memory access function is the function that has less computation but a lot of data transfer operations. This paper took the bitwise function as the example, studied and implemented the parallel and the optimizing methods of the continuously independent data and intensive memory access function on GPU platforms. Based on the OpenCL framework, this paper studied and compared various optimizing methods,such as vectorizing, threads organizing, and instruction selecting, and finally used these methods to implement the cross-platform transfer of the bitwise function among different platforms. The study tested the function's execution time without data transfer both on AMD GPU and NVIDIA GPU platforms. On the AMD Radeon HD 5850 platform, the performance has reached 40 times faster than the CPU version in OpenCV library, 90 times faster on AMD Radeon HD 7970 platform, and 60 times faster on NVIDIA GPU Tesla C2050 platform. On NVIDIA GPU Tesla C2050 platform, the speedup is 1.5 comparing with the CUDA version in OpenCV library

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials